How to buy Evotec SE stock in Canada

Evotec SE is a drug manufacturers - specialty & generic business based in the US. Evotec SE shares (EVO) are listed on the NASDAQ and all prices are listed in US Dollars.

Its last market close was $3.31 – a decrease of 5.7% over the previous week. Evotec SE employs 5,007 staff and has a trailing 12-month revenue of around $777.1 million.

Our top picks for where to buy Evotec SE ADR stock

Buy Evotec SE stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

Evotec SE stock price (NASDAQ: EVO)

Use our graph to track the performance of EVO stocks over time.

Evotec SE stocks at a glance

• Key figures

Information last updated 2025-03-28.

Latest market close	$3.31
52-week range	$2.85 - $7.98
50-day moving average more info button	$4.08
200-day moving average more info button	$4.12
Wall St. target price	$7.07
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.52

Is it a good time to buy Evotec SE stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Is Evotec SE stock undervalued or overvalued?

Valuing Evotec SE stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Evotec SE's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Evotec SE's EBITDA

Evotec SE's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $15.9 million.

The EBITDA is a measure of a Evotec SE's overall financial performance and is widely used to measure a its profitability.

Evotec SE financials

Revenue TTM	$777.1 million
Gross profit TTM	$106.5 million
Return on assets TTM	-1.77%
Return on equity TTM	-16.25%
Profit margin	-22.05%
Book value	$5.46
Market Capitalization more info button	$1.2 billion

TTM: trailing 12 months

Evotec SE stock dividends

We're not expecting Evotec SE to pay a dividend over the next 12 months.

Have Evotec SE's stocks ever split?

Evotec SE's stocks were split on a 4:1 basis on 19 October 2021 . So if you had owned 1 share the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your Evotec SE stocks – just the quantity. However, indirectly, the new 75% lower stock price could have impacted the market appetite for Evotec SE stocks, which in turn could have impacted Evotec SE's stock price.

Evotec SE stock price volatility

Over the last 12 months, Evotec SE's stocks have ranged in value from as little as $2.85 up to $7.98. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Evotec SE's is 0.962. This would suggest that Evotec SE's stocks are less volatile than average (for this exchange).

Evotec SE overview

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany..

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of Evotec SE is owned by institutions?
Currently 2.518% of Evotec SE stocks are held by institutions. How many people work for Evotec SE?
Latest data suggests 5,007 work at Evotec SE. When does the fiscal year end for Evotec SE?
Evotec SE's fiscal year ends in December. Where is Evotec SE based?
Evotec SE's address is: Essener Bogen 7, Hamburg, Germany, 22419 What is Evotec SE's ISIN number?
Evotec SE's international securities identification number is: US30050E1055

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.